Albert Giralt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Albert Giralt has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Lluis Fajas
Center for Integrative Genomics (CIG), University of Lausanne, Faculty of Biology and Medicine, Lausanne, Switzerland
16 shared publications - Judit Castillo-Armengol
Center for Integrative Genomics University of Lausanne Lausanne Switzerland
11 shared publications Lianjun Zhang
11 shared publicationsAnita Nasrallah
10 shared publicationsMeritxell Orpinell
10 shared publications- Angélique Pabois
INSERM UMR1064, Nantes University Hospital, Nantes, France
9 shared publications
Latest Publications
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival
Cyclin-dependent kinase 4 (CDK4) is well-known for its role in regulating the cell cycle, however, its role in cancer metabolism, especially mTOR signaling, is undefined. In this study, we established a connection between CDK4 and lysosomes, an emerging metabolic organelle crucial for mTORC1 activation. On the one hand, CDK4 phosphorylated the tumor suppressor folliculin (FLCN), regulating mTORC1 recruitment to the lysosomal surface in response to amino acids. On the other hand, CDK4 directly regulated lysosomal function and was essential for lysosomal degradation, ultimately regulating mTORC1 activity. Pharmacologic inhibition or genetic inactivation of CDK4, other than retaining FLCN at the lysosomal surface, led to the accumulation of undigested material inside lysosomes, which impaired the autophagic flux and induced cancer cell senescence in vitro and in xenograft models. Importantly, the use of CDK4 inhibitors in therapy is known to cause senescence but not cell death. To overcome this phenomenon and based on our findings, we increased the autophagic flux in cancer cells by using an AMPK activator in combination with a CDK4 inhibitor. The cotreatment induced autophagy (AMPK activation) and impaired lysosomal function (CDK4 inhibition), resulting in cell death and tumor regression. Altogether, we uncovered a previously unknown role for CDK4 in lysosomal biology and propose a novel therapeutic strategy to target cancer cells.Significance:These findings uncover a novel function of CDK4 in lysosomal biology, which promotes cancer progression by activating mTORC1; targeting this function offers a new therapeutic strategy for cancer treatment.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival
Cyclin-dependent kinase 4 (CDK4) is well-known for its role in regulating the cell cycle, however, its role in cancer metabolism, especially mTOR signaling, is undefined. In this study, we established a connection between CDK4 and lysosomes, an emerging metabolic organelle crucial for mTORC1 activation. On the one hand, CDK4 phosphorylated the tumor suppressor folliculin (FLCN), regulating mTORC1 recruitment to the lysosomal surface in response to amino acids. On the other hand, CDK4 directly regulated lysosomal function and was essential for lysosomal degradation, ultimately regulating mTORC1 activity. Pharmacologic inhibition or genetic inactivation of CDK4, other than retaining FLCN at the lysosomal surface, led to the accumulation of undigested material inside lysosomes, which impaired the autophagic flux and induced cancer cell senescence in vitro and in xenograft models. Importantly, the use of CDK4 inhibitors in therapy is known to cause senescence but not cell death. To overcome this phenomenon and based on our findings, we increased the autophagic flux in cancer cells by using an AMPK activator in combination with a CDK4 inhibitor. The cotreatment induced autophagy (AMPK activation) and impaired lysosomal function (CDK4 inhibition), resulting in cell death and tumor regression. Altogether, we uncovered a previously unknown role for CDK4 in lysosomal biology and propose a novel therapeutic strategy to target cancer cells.Significance:These findings uncover a novel function of CDK4 in lysosomal biology, which promotes cancer progression by activating mTORC1; targeting this function offers a new therapeutic strategy for cancer treatment.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival
Supplementary Tables. Supplementary Table 1. Target sequences for guide RNA used to create KO stable cell lines with CRISP/Cas9 technology, Supplementary Table 2. Primers used for qPCR Analysis of Transcription Factor EB (TFEB) regulated genes (human), Supplementary Table 3. Primers used for qPCR Analysis of Senescence genes (human), Supplementary Table 4. Primers used for qPCR Analysis of housekeeping genes (human), Supplementary Table 5. Primers used for FLCN mutagenesis
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival
Supplementary Tables. Supplementary Table 1. Target sequences for guide RNA used to create KO stable cell lines with CRISP/Cas9 technology, Supplementary Table 2. Primers used for qPCR Analysis of Transcription Factor EB (TFEB) regulated genes (human), Supplementary Table 3. Primers used for qPCR Analysis of Senescence genes (human), Supplementary Table 4. Primers used for qPCR Analysis of housekeeping genes (human), Supplementary Table 5. Primers used for FLCN mutagenesis
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival
Supplementary Tables. Supplementary Table 1. Target sequences for guide RNA used to create KO stable cell lines with CRISP/Cas9 technology, Supplementary Table 2. Primers used for qPCR Analysis of Transcription Factor EB (TFEB) regulated genes (human), Supplementary Table 3. Primers used for qPCR Analysis of Senescence genes (human), Supplementary Table 4. Primers used for qPCR Analysis of housekeeping genes (human), Supplementary Table 5. Primers used for FLCN mutagenesis
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival
Supplementary Tables. Supplementary Table 1. Target sequences for guide RNA used to create KO stable cell lines with CRISP/Cas9 technology, Supplementary Table 2. Primers used for qPCR Analysis of Transcription Factor EB (TFEB) regulated genes (human), Supplementary Table 3. Primers used for qPCR Analysis of Senescence genes (human), Supplementary Table 4. Primers used for qPCR Analysis of housekeeping genes (human), Supplementary Table 5. Primers used for FLCN mutagenesis
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival
Cyclin-dependent kinase 4 (CDK4) is well-known for its role in regulating the cell cycle, however, its role in cancer metabolism, especially mTOR signaling, is undefined. In this study, we established a connection between CDK4 and lysosomes, an emerging metabolic organelle crucial for mTORC1 activation. On the one hand, CDK4 phosphorylated the tumor suppressor folliculin (FLCN), regulating mTORC1 recruitment to the lysosomal surface in response to amino acids. On the other hand, CDK4 directly regulated lysosomal function and was essential for lysosomal degradation, ultimately regulating mTORC1 activity. Pharmacologic inhibition or genetic inactivation of CDK4, other than retaining FLCN at the lysosomal surface, led to the accumulation of undigested material inside lysosomes, which impaired the autophagic flux and induced cancer cell senescence in vitro and in xenograft models. Importantly, the use of CDK4 inhibitors in therapy is known to cause senescence but not cell death. To overcome this phenomenon and based on our findings, we increased the autophagic flux in cancer cells by using an AMPK activator in combination with a CDK4 inhibitor. The cotreatment induced autophagy (AMPK activation) and impaired lysosomal function (CDK4 inhibition), resulting in cell death and tumor regression. Altogether, we uncovered a previously unknown role for CDK4 in lysosomal biology and propose a novel therapeutic strategy to target cancer cells.Significance:These findings uncover a novel function of CDK4 in lysosomal biology, which promotes cancer progression by activating mTORC1; targeting this function offers a new therapeutic strategy for cancer treatment.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival
Cyclin-dependent kinase 4 (CDK4) is well-known for its role in regulating the cell cycle, however, its role in cancer metabolism, especially mTOR signaling, is undefined. In this study, we established a connection between CDK4 and lysosomes, an emerging metabolic organelle crucial for mTORC1 activation. On the one hand, CDK4 phosphorylated the tumor suppressor folliculin (FLCN), regulating mTORC1 recruitment to the lysosomal surface in response to amino acids. On the other hand, CDK4 directly regulated lysosomal function and was essential for lysosomal degradation, ultimately regulating mTORC1 activity. Pharmacologic inhibition or genetic inactivation of CDK4, other than retaining FLCN at the lysosomal surface, led to the accumulation of undigested material inside lysosomes, which impaired the autophagic flux and induced cancer cell senescence in vitro and in xenograft models. Importantly, the use of CDK4 inhibitors in therapy is known to cause senescence but not cell death. To overcome this phenomenon and based on our findings, we increased the autophagic flux in cancer cells by using an AMPK activator in combination with a CDK4 inhibitor. The cotreatment induced autophagy (AMPK activation) and impaired lysosomal function (CDK4 inhibition), resulting in cell death and tumor regression. Altogether, we uncovered a previously unknown role for CDK4 in lysosomal biology and propose a novel therapeutic strategy to target cancer cells.Significance:These findings uncover a novel function of CDK4 in lysosomal biology, which promotes cancer progression by activating mTORC1; targeting this function offers a new therapeutic strategy for cancer treatment.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures with Figure legends. from CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival
Supplementary Figures and Supplementary Figure legends. Supplementary Fig. 1.- CDK4 inhibition or depletion decreases mTORC1 activity in several cancer cell lines, Supplementary Fig. 2.- CDK4 effects on mTORC1 are α-ketoglutarate and E2F1-independent, Supplementary Fig. 3.- CDK4 phosphorylates FLCN, Supplementary Fig. 4.- CDK4 regulates mTORC1 activity through phosphorylating FLCN, Supplementary Fig. 5.- CDK4 inhibition or depletion increases lysosomal mass, Supplementary Fig. 6.- Hematoxylin and eosin staining and gene expression analysis of tumors from mice treated with or without LY2835219, Supplementary Fig. 7.- In vitro cell death analysis and in vivo electron microscopy analysis of tumors treated with DMSO, LY2835219, A769662 and the combination of A769662 with LY2835219
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures with Figure legends. from CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival
Supplementary Figures and Supplementary Figure legends. Supplementary Fig. 1.- CDK4 inhibition or depletion decreases mTORC1 activity in several cancer cell lines, Supplementary Fig. 2.- CDK4 effects on mTORC1 are α-ketoglutarate and E2F1-independent, Supplementary Fig. 3.- CDK4 phosphorylates FLCN, Supplementary Fig. 4.- CDK4 regulates mTORC1 activity through phosphorylating FLCN, Supplementary Fig. 5.- CDK4 inhibition or depletion increases lysosomal mass, Supplementary Fig. 6.- Hematoxylin and eosin staining and gene expression analysis of tumors from mice treated with or without LY2835219, Supplementary Fig. 7.- In vitro cell death analysis and in vivo electron microscopy analysis of tumors treated with DMSO, LY2835219, A769662 and the combination of A769662 with LY2835219
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures with Figure legends. from CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival
Supplementary Figures and Supplementary Figure legends. Supplementary Fig. 1.- CDK4 inhibition or depletion decreases mTORC1 activity in several cancer cell lines, Supplementary Fig. 2.- CDK4 effects on mTORC1 are α-ketoglutarate and E2F1-independent, Supplementary Fig. 3.- CDK4 phosphorylates FLCN, Supplementary Fig. 4.- CDK4 regulates mTORC1 activity through phosphorylating FLCN, Supplementary Fig. 5.- CDK4 inhibition or depletion increases lysosomal mass, Supplementary Fig. 6.- Hematoxylin and eosin staining and gene expression analysis of tumors from mice treated with or without LY2835219, Supplementary Fig. 7.- In vitro cell death analysis and in vivo electron microscopy analysis of tumors treated with DMSO, LY2835219, A769662 and the combination of A769662 with LY2835219
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures with Figure legends. from CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival
Supplementary Figures and Supplementary Figure legends. Supplementary Fig. 1.- CDK4 inhibition or depletion decreases mTORC1 activity in several cancer cell lines, Supplementary Fig. 2.- CDK4 effects on mTORC1 are α-ketoglutarate and E2F1-independent, Supplementary Fig. 3.- CDK4 phosphorylates FLCN, Supplementary Fig. 4.- CDK4 regulates mTORC1 activity through phosphorylating FLCN, Supplementary Fig. 5.- CDK4 inhibition or depletion increases lysosomal mass, Supplementary Fig. 6.- Hematoxylin and eosin staining and gene expression analysis of tumors from mice treated with or without LY2835219, Supplementary Fig. 7.- In vitro cell death analysis and in vivo electron microscopy analysis of tumors treated with DMSO, LY2835219, A769662 and the combination of A769662 with LY2835219
- 15 October 2019
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 79 (20) , 5245-5259
CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival
Cyclin-dependent kinase 4 (CDK4) is well-known for its role in regulating the cell cycle, however, its role in cancer metabolism, especially mTOR signaling, is undefined. In this study, we established a connection between CDK4 and lysosomes, an emerging metabolic organelle crucial for mTORC1 activation. On the one hand, CDK4 phosphorylated the tumor suppressor folliculin (FLCN), regulating mTORC1 recruitment to the lysosomal surface in response to amino acids. On the other hand, CDK4 directly regulated lysosomal function and was essential for lysosomal degradation, ultimately regulating mTORC1 activity. Pharmacologic inhibition or genetic inactivation of CDK4, other than retaining FLCN at the lysosomal surface, led to the accumulation of undigested material inside lysosomes, which impaired the autophagic flux and induced cancer cell senescence in vitro and in xenograft models. Importantly, the use of CDK4 inhibitors in therapy is known to cause senescence but not cell death. To overcome this phenomenon and based on our findings, we increased the autophagic flux in cancer cells by using an AMPK activator in combination with a CDK4 inhibitor. The cotreatment induced autophagy (AMPK activation) and impaired lysosomal function (CDK4 inhibition), resulting in cell death and tumor regression. Altogether, we uncovered a previously unknown role for CDK4 in lysosomal biology and propose a novel therapeutic strategy to target cancer cells. Significance: These findings uncover a novel function of CDK4 in lysosomal biology, which promotes cancer progression by activating mTORC1; targeting this function offers a new therapeutic strategy for cancer treatment.
- 15 October 2019
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 79 (20) , 5245-5259
CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival
Cyclin-dependent kinase 4 (CDK4) is well-known for its role in regulating the cell cycle, however, its role in cancer metabolism, especially mTOR signaling, is undefined. In this study, we established a connection between CDK4 and lysosomes, an emerging metabolic organelle crucial for mTORC1 activation. On the one hand, CDK4 phosphorylated the tumor suppressor folliculin (FLCN), regulating mTORC1 recruitment to the lysosomal surface in response to amino acids. On the other hand, CDK4 directly regulated lysosomal function and was essential for lysosomal degradation, ultimately regulating mTORC1 activity. Pharmacologic inhibition or genetic inactivation of CDK4, other than retaining FLCN at the lysosomal surface, led to the accumulation of undigested material inside lysosomes, which impaired the autophagic flux and induced cancer cell senescence in vitro and in xenograft models. Importantly, the use of CDK4 inhibitors in therapy is known to cause senescence but not cell death. To overcome this phenomenon and based on our findings, we increased the autophagic flux in cancer cells by using an AMPK activator in combination with a CDK4 inhibitor. The cotreatment induced autophagy (AMPK activation) and impaired lysosomal function (CDK4 inhibition), resulting in cell death and tumor regression. Altogether, we uncovered a previously unknown role for CDK4 in lysosomal biology and propose a novel therapeutic strategy to target cancer cells. Significance: These findings uncover a novel function of CDK4 in lysosomal biology, which promotes cancer progression by activating mTORC1; targeting this function offers a new therapeutic strategy for cancer treatment.
- Open Access
- 1 May 2018
- Published by Elsevier in Molecular Metabolism
- Vol. 11, 104-112
E2F1 promotes hepatic gluconeogenesis and contributes to hyperglycemia during diabetes
- 1 May 2018
- Published by Elsevier in Molecular Metabolism
- Vol. 11, 104-112
Open AccessE2F1 promotes hepatic gluconeogenesis and contributes to hyperglycemia during diabetes